

Development of gene therapy for NMIBC using bispecific RNAi



ONCOLOGY	Non-Clinical
Product Type	Bispecific shRNA encoding oncolytic virus product
Indication	Non muscle invasive bladder cancer (NMIBC)
Target	mTOR, Stat3
MoA(Mechanism of Action)	Specifically infects and replicates in cancer cells through cancer-specific promoter & Down-regulating mTOR and STAT3 mRNA expressions via bispecific shRNA
Competitiveness	First in class: Combines oncolytic virus and RNAi technology Bispecific RNAi therapy enables low side effects and efficient gene targeting & Double anti-tumor effect due to the tumor cell lysis and downregulation of the target genes
Development Stage	Non-Clinical
Route of Administration	Instillation